Argenx

Argenx is a clinical-stage biotechnology company developing a differentiated antibody-based therapy for severe autoimmune diseases and cancer. The company focuses on advancing promising candidate products, which may be first-in-class for novel targets or first-in-class for known but complex targets, to address diseases with significant unmet medical needs.